89bio, Inc.
NASDAQ Global Market•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Rohan Palekar
- Full Time Employees
- 93
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 142 Sansome Street San Francisco CA United States of America 94104
- IPO Date
- Nov 11, 2019
- CIK
- 0001785173
- Website
- 89bio.com
- Similar Companies
- Business
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Company News
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio to Participate in Upcoming Investor Conferences
89bio Reports First Quarter 2025 Financial Results and Corporate Updates
89bio: A Buy With Strong Market Opportunity In MASH And SHTG
Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year?
89bio to Participate in the Leerink Partners Global Healthcare Conference
89bio price target lowered by $8 at H.C. Wainwright, here's why
89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
Should You Buy 89BIO (ETNB) After Golden Cross?
Wall Street Analysts See a 171.42% Upside in 89BIO (ETNB): Can the Stock Really Move This High?
Insider Buying Surges in February, Especially in These 6 Stocks
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wall Street Analysts Think 89BIO (ETNB) Could Surge 219.06%: Read This Before Placing a Bet
89bio's Pegozafermin Is Now Gaining Momentum
89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants
Why 89bio Stock Lagged the Market Today
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants